glycine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to determine whether S-4-carboxy-3-hydroxyphenylglycine (S)-4C3HPG, a mixed group I glutamate metabotropic receptor antagonist and a group II agonist, attenuated parkinsonian-like muscle rigidity in rats." | 3.71 | (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Pilc, A; Wardas, J; Wolfarth, S, 2001) |
| "To study parkinsonism, dementia, dystonia, and amyotrophy as subphenotypes of SCA2, and to explore the effect of CAG repeats at different loci and of mitochondrial polymorphism A10398G as modifiers of phenotype." | 1.46 | Neurological phenotypes in spinocerebellar ataxia type 2: Role of mitochondrial polymorphism A10398G and other risk factors. ( Augustin, MC; Barsottini, O; Jardim, LB; Locks-Coelho, LD; Monte, TL; Pedroso, JL; Pereira, FS; Reckziegel, EDR; Santos, ASP; Saraiva-Pereira, ML; Vargas, FR, 2017) |
| "Perry syndrome is a rare form of autosomal dominant Parkinsonism with respiratory failure recently defined as being due to mutations in the DCTN1 gene." | 1.36 | Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure. ( Fish, M; Hack, M; Majounie, E; Morris, HR; Newsway, V; Rohrer, JD; Warren, JD; Williams, N, 2010) |
| "The mean age at onset for parkinsonism was 60 years, range 30-79 years; fewer than 20% of the patients had symptoms before the age 50 years, while by 75 years >90% of them had developed symptoms." | 1.35 | Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. ( Benecke, R; Berg, D; Bonifati, V; Brown, L; Cras, P; De Deyn, PP; Engelborghs, S; Farrer, MJ; Foroud, T; Gaig, C; Gasser, T; Gibson, JM; Goldwurm, S; Guidi, M; Hagenah, J; Haugarvoll, K; Kachergus, JM; Klein, C; Nichols, WC; Nuytemans, K; Pals, P; Pickut, B; Rademakers, R; Riboldazzi, G; Ross, OA; Samii, A; Tan, EK; Theuns, J; Tolosa, E; Uitti, RJ; Van Broeckhoven, C; Walter, U; Wszolek, ZK; Zabetian, CP, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Bourque, M | 3 |
| Grégoire, L | 3 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 4 |
| Coon, EA | 1 |
| Rocca, W | 1 |
| Melson, CS | 1 |
| Ahlskog, JE | 1 |
| Matsumoto, JY | 1 |
| Low, PA | 1 |
| Singer, W | 1 |
| Monte, TL | 1 |
| Pereira, FS | 1 |
| Reckziegel, EDR | 1 |
| Augustin, MC | 1 |
| Locks-Coelho, LD | 1 |
| Santos, ASP | 1 |
| Pedroso, JL | 1 |
| Barsottini, O | 1 |
| Vargas, FR | 1 |
| Saraiva-Pereira, ML | 1 |
| Jardim, LB | 1 |
| Zheng, Q | 1 |
| Yin, J | 1 |
| Zhu, L | 1 |
| Jiao, L | 1 |
| Xu, Z | 1 |
| Goldstein, DA | 1 |
| Dunn, SE | 1 |
| Karberg, K | 1 |
| Sun, XR | 1 |
| Chen, L | 1 |
| Chen, WF | 1 |
| Xue, Y | 1 |
| Yung, WH | 1 |
| Munhoz, RP | 1 |
| Teive, HA | 1 |
| Francisco, AN | 1 |
| Raskin, S | 1 |
| Rogaeva, E | 1 |
| Wider, C | 1 |
| Dachsel, JC | 2 |
| Farrer, MJ | 4 |
| Dickson, DW | 2 |
| Tsuboi, Y | 1 |
| Wszolek, ZK | 2 |
| Newsway, V | 1 |
| Fish, M | 1 |
| Rohrer, JD | 1 |
| Majounie, E | 1 |
| Williams, N | 1 |
| Hack, M | 1 |
| Warren, JD | 1 |
| Morris, HR | 1 |
| Venero, JL | 1 |
| Mauriño, R | 1 |
| Machado, A | 1 |
| Santiago, M | 1 |
| Valldeoriola, F | 2 |
| Gaig, C | 3 |
| Muxí, A | 1 |
| Navales, I | 1 |
| Paredes, P | 1 |
| Lomeña, F | 1 |
| De la Cerda, A | 1 |
| Buongiorno, M | 1 |
| Ezquerra, M | 2 |
| Santacruz, P | 1 |
| Martí, MJ | 2 |
| Tolosa, E | 3 |
| Wang, G | 1 |
| Fan, XN | 1 |
| Tan, YY | 1 |
| Cheng, Q | 1 |
| Chen, SD | 1 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| van Nuenen, BF | 1 |
| Helmich, RC | 1 |
| Ferraye, M | 1 |
| Thaler, A | 1 |
| Hendler, T | 1 |
| Orr-Urtreger, A | 1 |
| Mirelman, A | 1 |
| Bressman, S | 1 |
| Marder, KS | 1 |
| Giladi, N | 1 |
| van de Warrenburg, BP | 1 |
| Bloem, BR | 1 |
| Toni, I | 1 |
| Wu, RM | 1 |
| Bounds, R | 1 |
| Lincoln, S | 1 |
| Hulihan, M | 1 |
| Lin, CH | 1 |
| Hwu, WL | 1 |
| Chen, J | 1 |
| Gwinn-Hardy, K | 1 |
| Farrer, M | 1 |
| Kaneda, K | 1 |
| Tachibana, Y | 1 |
| Imanishi, M | 1 |
| Kita, H | 1 |
| Shigemoto, R | 1 |
| Nambu, A | 1 |
| Takada, M | 1 |
| Rajput, A | 1 |
| Robinson, CA | 1 |
| Ross, OA | 3 |
| Lincoln, SJ | 1 |
| Cobb, SA | 1 |
| Rajput, ML | 1 |
| Schüpbach, M | 1 |
| Lohmann, E | 1 |
| Anheim, M | 1 |
| Lesage, S | 1 |
| Czernecki, V | 1 |
| Yaici, S | 1 |
| Worbe, Y | 1 |
| Charles, P | 1 |
| Welter, ML | 1 |
| Pollak, P | 1 |
| Dürr, A | 1 |
| Agid, Y | 1 |
| Brice, A | 1 |
| Karunakaran, S | 1 |
| Diwakar, L | 1 |
| Saeed, U | 1 |
| Agarwal, V | 1 |
| Ramakrishnan, S | 1 |
| Iyengar, S | 1 |
| Ravindranath, V | 1 |
| González-Fernández, MC | 1 |
| Lezcano, E | 1 |
| Gómez-Esteban, JC | 1 |
| Gómez-Busto, F | 1 |
| Velasco, F | 1 |
| Alvarez-Alvarez, M | 1 |
| Rodríguez-Martínez, MB | 1 |
| Ciordia, R | 1 |
| Zarranz, JJ | 1 |
| Mata, IF | 1 |
| de Pancorbo, MM | 1 |
| Vernon, AC | 1 |
| Zbarsky, V | 1 |
| Datla, KP | 1 |
| Croucher, MJ | 1 |
| Dexter, DT | 1 |
| Haugarvoll, K | 1 |
| Rademakers, R | 1 |
| Kachergus, JM | 1 |
| Nuytemans, K | 1 |
| Gibson, JM | 1 |
| Tan, EK | 1 |
| Goldwurm, S | 1 |
| Guidi, M | 1 |
| Riboldazzi, G | 1 |
| Brown, L | 1 |
| Walter, U | 1 |
| Benecke, R | 1 |
| Berg, D | 1 |
| Gasser, T | 1 |
| Theuns, J | 1 |
| Pals, P | 1 |
| Cras, P | 1 |
| De Deyn, PP | 1 |
| Engelborghs, S | 1 |
| Pickut, B | 1 |
| Uitti, RJ | 1 |
| Foroud, T | 1 |
| Nichols, WC | 1 |
| Hagenah, J | 1 |
| Klein, C | 1 |
| Samii, A | 1 |
| Zabetian, CP | 1 |
| Bonifati, V | 1 |
| Van Broeckhoven, C | 1 |
| Muñoz, E | 1 |
| Lladó, A | 1 |
| Rey, MJ | 1 |
| Cardozo, A | 1 |
| Molinuevo, JL | 1 |
| Lorenc-Koci, E | 1 |
| Wardas, J | 1 |
| Wolfarth, S | 1 |
| Pilc, A | 1 |
| Calon, F | 1 |
| Morissette, M | 1 |
| Ghribi, O | 1 |
| Goulet, M | 1 |
| Grondin, R | 1 |
| Blanchet, PJ | 1 |
| Bédard, PJ | 1 |
| Lavedan, C | 1 |
| Buchholtz, S | 1 |
| Nussbaum, RL | 1 |
| Albin, RL | 1 |
| Polymeropoulos, MH | 1 |
1 trial available for glycine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
Topics: Adult; Aged; Deep Brain Stimulation; Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine P | 2007 |
25 other studies available for glycine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Conjugal multiple system atrophy: Chance, shared risk factors, or evidence of transmissibility?
Topics: Autonomic Nervous System Diseases; Female; Glycine; Glyphosate; Herbicides; Humans; Male; Middle Age | 2019 |
Neurological phenotypes in spinocerebellar ataxia type 2: Role of mitochondrial polymorphism A10398G and other risk factors.
Topics: Adult; Aged; Alanine; Ataxin-2; Dementia; Dystonia; Female; Genetic Predisposition to Disease; Glyci | 2017 |
Reply for the comment on "Reversible Parkinsonism induced by acute exposure glyphosate".
Topics: Glycine; Glyphosate; Humans; Parkinsonian Disorders | 2018 |
"Reversible Parkinsonism" following glyphosate exposure.
Topics: Glycine; Glyphosate; Humans; Parkinsonian Disorders | 2018 |
Electrophysiological and behavioral effects of group III metabotropic glutamate receptors on pallidal neurons in normal and parkinsonian rats.
Topics: Action Potentials; Aminobutyrates; Animals; Globus Pallidus; Glycine; Male; Neurons; Oxidopamine; Pa | 2013 |
Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation.
Topics: Female; Functional Laterality; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase- | 2009 |
Elucidating the genetics and pathology of Perry syndrome.
Topics: Adult; Age of Onset; Aged; Animals; Brain; Chlorocebus aethiops; COS Cells; Depression; DNA-Binding | 2010 |
Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure.
Topics: Arginine; Behavioral Symptoms; DNA Mutational Analysis; Dopamine Agents; Dynactin Complex; Glycine; | 2010 |
Striatal ablation of GABAergic neurons prevents the in vivo neuroprotective effect of DCG-IV against the MPP+-induced neurotoxicity on dopaminergic nerve terminals.
Topics: Animals; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; | 2010 |
123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Female; Glycine; Heart; Humans; Leucine-Rich | 2011 |
Parkinsonism after chronic occupational exposure to glyphosate.
Topics: Adult; Chemical Industry; Female; Glycine; Glyphosate; Herbicides; Humans; Occupational Exposure; Pa | 2011 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
Topics: Adult; Analysis of Variance; Biomechanical Phenomena; Brain; Cerebral Cortex; DNA Mutational Analysi | 2012 |
Parkin mutations and early-onset parkinsonism in a Taiwanese cohort.
Topics: Adult; Arginine; Cohort Studies; DNA Mutational Analysis; Exons; Family Health; Female; Glycine; Hum | 2005 |
Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Benzoate | 2005 |
Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
Topics: Aged; alpha-Synuclein; Brain; Cell Line; Disability Evaluation; Disease Progression; Female; Glycine | 2006 |
Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Alkynes; Animals; Antioxidants; Antipa | 2007 |
Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.
Topics: Adult; Aged; Arginine; DNA Mutational Analysis; Family Health; Female; Genetic Predisposition to Dis | 2007 |
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Topics: Animals; Benzoates; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Ac | 2007 |
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Arginine; Cysteine; DNA Mutational Analysis | 2008 |
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Topics: Dementia; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Glyci | 2008 |
(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Electromyography; Glycine; | 2001 |
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agoni | 2002 |
A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration.
Topics: Adult; Age of Onset; Brain; Cytoskeleton; DNA Mutational Analysis; Female; Genetic Testing; Glycine; | 2002 |